Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is placed sixth on our list of cheap pharmaceutical stocks.
TheFly reported on February 10 that Truist Securities analyst Les Sulewski raised its price target on COLL to $58 from $55 and gave it a Buy rating. The analyst emphasized the robustness of the company’s wider pain management portfolio and offered a positive assessment of its ongoing momentum with Jornay.
Additionally, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) gave a business update and its full-year 2026 financial outlook in January. The company also highlighted expectations for continuing operational strength. The company says that it expects net product revenue to range from $805 million to $825 million for the year. Within that range, Jornay PM is anticipated to produce net sales of atleast $190 million to $200 million, which shows its importance to the overall expansion plan. Furthermore, according to COLL, adjusted EBITDA will range from $455 million to $475 million, indicating strong profitability and careful cost control. The company also has confidence in the longevity of its portfolio and its ability to sustain earnings momentum through 2026, as indicated by the updated projection.
Collegium Pharmaceutical, Inc. (NASDQAQ:COLL) is a U.S. pharmaceutical company focused on developing and commercializing innovative pain management therapies, including abuse-deterrent opioid formulations, leveraging science-based solutions to improve patient safety and treatment outcomes.
While we acknowledge the potential of COLL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.
Disclosure: None.
